{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:06:05Z","timestamp":1788314765616,"version":"build-2803163510"},"reference-count":80,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.cld.2026.04.010","type":"journal-article","created":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T23:03:26Z","timestamp":1784761406000},"page":"625-642","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Cholestatic Pruritus"],"prefix":"10.1016","volume":"30","author":[{"given":"Ehiamen T.","family":"Okoruwa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlyn J.","family":"Mayo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.cld.2026.04.010_bib1","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1136\/flgastro-2015-100618","article-title":"A systematic approach to the management of cholestatic pruritus in primary biliary cirrhosis","volume":"7","author":"Hegade","year":"2016","journal-title":"Frontline Gastroenterol"},{"issue":"3","key":"10.1016\/j.cld.2026.04.010_bib2","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.abd.2021.06.007","article-title":"Cholestatic pruritus: a knowledge update","volume":"97","author":"Nietsche","year":"2022","journal-title":"An Bras Dermatol"},{"issue":"2","key":"10.1016\/j.cld.2026.04.010_bib3","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.clinre.2010.10.007","article-title":"Pathophysiology and current management of pruritus in liver disease","volume":"35","author":"Kremer","year":"2011","journal-title":"Clin Res Hepatol Gastroenterol"},{"issue":"1","key":"10.1016\/j.cld.2026.04.010_bib4","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1002\/hep.26909","article-title":"Pruritus in cholestasis: facts and fiction","volume":"60","author":"Beuers","year":"2014","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2026.04.010_bib5","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1007\/s10620-022-07581-x","article-title":"Impact of pruritus on quality of life and current treatment patterns in patients with primary biliary cholangitis","volume":"68","author":"Mayo","year":"2023","journal-title":"Dig Dis Sci"},{"issue":"3","key":"10.1016\/j.cld.2026.04.010_bib6","doi-asserted-by":"crossref","DOI":"10.1097\/HC9.0000000000000635","article-title":"Pervasive role of pruritus in impaired quality of life in patients with primary biliary cholangitis: data from the GLIMMER study","volume":"9","author":"Smith","year":"2025","journal-title":"Hepatol Commun"},{"issue":"2","key":"10.1016\/j.cld.2026.04.010_bib7","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1111\/liv.12026","article-title":"Sleep-wake profiles in patients with primary biliary cirrhosis","volume":"33","author":"Montagnese","year":"2013","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.cld.2026.04.010_bib8","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2009.04.009","article-title":"EASL clinical practice guidelines: management of cholestatic liver diseases","volume":"51","year":"2009","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2026.04.010_bib9","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","article-title":"EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis","volume":"67","author":"Liver","year":"2017","journal-title":"J Hepatol"},{"issue":"3","key":"10.1016\/j.cld.2026.04.010_bib10","doi-asserted-by":"crossref","first-page":"E252","DOI":"10.1111\/hepr.12978","article-title":"Prevalence of pruritus in patients with chronic liver disease: a multicenter study","volume":"48","author":"Oeda","year":"2018","journal-title":"Hepatol Res"},{"issue":"1","key":"10.1016\/j.cld.2026.04.010_bib11","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2340\/00015555-0350","article-title":"Itch in primary biliary cirrhosis: a patients\u2019 perspective","volume":"88","author":"Rishe","year":"2008","journal-title":"Acta Derm Venereol"},{"issue":"9","key":"10.1016\/j.cld.2026.04.010_bib12","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.jfma.2016.05.006","article-title":"Quality of life among patients suffering from cholestatic liver disease-induced pruritus: a systematic review","volume":"115","author":"Jin","year":"2016","journal-title":"J Formos Med Assoc"},{"issue":"1","key":"10.1016\/j.cld.2026.04.010_bib13","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1002\/lt.20001","article-title":"Treatment of refractory cholestatic pruritus after liver transplantation with albumin dialysis","volume":"10","author":"Bellmann","year":"2004","journal-title":"Liver Transplant"},{"issue":"6","key":"10.1016\/j.cld.2026.04.010_bib14","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/j.1572-0241.2004.30204.x","article-title":"Extracorporeal albumin dialysis: a procedure for prolonged relief of intractable pruritus in patients with primary biliary cirrhosis","volume":"99","author":"Par\u00e9s","year":"2004","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.cld.2026.04.010_bib15","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.sder.2011.04.009","article-title":"The itch of liver disease","volume":"30","author":"Bergasa","year":"2011","journal-title":"Semin Cutan Med Surg"},{"issue":"1","key":"10.1016\/j.cld.2026.04.010_bib16","first-page":"77","article-title":"Itch in liver disease: facts and speculations","volume":"52","author":"Ghent","year":"1979","journal-title":"Yale J Biol Med"},{"issue":"5","key":"10.1016\/j.cld.2026.04.010_bib17","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/S0016-5085(19)31870-0","article-title":"Elevations in skin tissue levels of bile acids in human cholestasis: relation to serum levels and topruritus","volume":"73","author":"Ghent","year":"1977","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.cld.2026.04.010_bib18","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1053\/j.gastro.2010.05.009","article-title":"Lysophosphatidic acid is a potential mediator of cholestatic pruritus","volume":"139","author":"Kremer","year":"2010","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.cld.2026.04.010_bib19","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1002\/hep.23821","article-title":"The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial","volume":"52","author":"Kuiper","year":"2010","journal-title":"Hepatology"},{"issue":"10311","key":"10.1016\/j.cld.2026.04.010_bib20","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1016\/S0140-6736(21)01256-3","article-title":"Efficacy and safety of maralixibat treatment in patients with alagille syndrome and cholestatic pruritus (ICONIC): a randomised phase 2 study","volume":"398","author":"Gonzales","year":"2021","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.cld.2026.04.010_bib21","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/S2468-1253(22)00093-0","article-title":"Odevixibat treatment in progressive familial intrahepatic cholestasis: a randomised, placebo-controlled, phase 3 trial","volume":"7","author":"Thompson","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2026.04.010_bib22","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/liv.15039","article-title":"Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis","volume":"42","author":"Kremer","year":"2022","journal-title":"Liver Int"},{"issue":"5","key":"10.1016\/j.cld.2026.04.010_bib23","article-title":"Cholestatic pruritus in children: conventional therapies and beyond","volume":"12","author":"Rodrigo","year":"2023","journal-title":"Biology (Basel)"},{"key":"10.1016\/j.cld.2026.04.010_bib24","article-title":"Cholestasis-associated pruritus and its pruritogens","volume":"8","author":"Langedijk","year":"2021","journal-title":"Front Med (Lausanne)"},{"issue":"3","key":"10.1016\/j.cld.2026.04.010_bib25","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/S0952-8180(02)00501-9","article-title":"Neuraxial opioid-induced pruritus: a review","volume":"15","author":"Szarvas","year":"2003","journal-title":"J Clin Anesth"},{"issue":"3","key":"10.1016\/j.cld.2026.04.010_bib26","doi-asserted-by":"crossref","first-page":"161","DOI":"10.7326\/0003-4819-123-3-199508010-00001","article-title":"Effects of naloxone infusions in patients with the pruritus of cholestasis. A double-blind, randomized, controlled trial","volume":"123","author":"Bergasa","year":"1995","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.cld.2026.04.010_bib27","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/S0016-5085(03)00879-5","article-title":"Pain as a complication of use of opiate antagonists for symptom control in cholestasis","volume":"125","author":"McRae","year":"2003","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.cld.2026.04.010_bib28","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.1111\/j.1572-0241.2007.01200.x","article-title":"The efficacy and safety of bile acid binding agents, opioid antagonists, or rifampin in the treatment of cholestasis-associated pruritus","volume":"102","author":"Tandon","year":"2007","journal-title":"Am J Gastroenterol"},{"issue":"2","key":"10.1016\/j.cld.2026.04.010_bib29","doi-asserted-by":"crossref","DOI":"10.2196\/30737","article-title":"Novel kappa-opioid receptor agonist for the treatment of cholestatic pruritus: systematic review","volume":"5","author":"Bailey","year":"2022","journal-title":"JMIR Dermatol"},{"issue":"10","key":"10.1016\/j.cld.2026.04.010_bib30","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1007\/s00535-018-1465-z","article-title":"Is patient-reported outcome improved by nalfurafine hydrochloride in patients with primary biliary cholangitis and refractory pruritus? A post-marketing, single-arm, prospective study","volume":"53","author":"Yagi","year":"2018","journal-title":"J Gastroenterol"},{"issue":"8","key":"10.1016\/j.cld.2026.04.010_bib31","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1016\/j.cgh.2023.02.005","article-title":"New treatment paradigms in primary biliary cholangitis","volume":"21","author":"Levy","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"16","key":"10.1016\/j.cld.2026.04.010_bib32","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1007\/s40265-021-01619-6","article-title":"First approval","volume":"81","author":"Deeks","year":"2021","journal-title":"Drugs"},{"issue":"12","key":"10.1016\/j.cld.2026.04.010_bib33","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1111\/j.1572-0241.2003.08662.x","article-title":"Long-term efficacy of sertraline as a treatment for cholestatic pruritus in patients with primary biliary cirrhosis","volume":"98","author":"Browning","year":"2003","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.cld.2026.04.010_bib34","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1002\/hep.21553","article-title":"Sertraline as a first-line treatment for cholestatic pruritus","volume":"45","author":"Mayo","year":"2007","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.cld.2026.04.010_bib35","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1002\/hep.28265","article-title":"Prognostic and mechanistic potential of progesterone sulfates in intrahepatic cholestasis of pregnancy and pruritus gravidarum","volume":"63","author":"Abu-Hayyeh","year":"2016","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.cld.2026.04.010_bib36","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1002\/hep.26055","article-title":"Intrahepatic cholestasis of pregnancy levels of sulfated progesterone metabolites inhibit farnesoid X receptor resulting in a cholestatic phenotype","volume":"57","author":"Abu-Hayyeh","year":"2013","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2026.04.010_bib37","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12876-019-1092-z","article-title":"Pruritus in patients with chronic liver disease and serum autotaxin levels in patients with primary biliary cholangitis","volume":"19","author":"Fujino","year":"2019","journal-title":"BMC Gastroenterol"},{"issue":"2","key":"10.1016\/j.cld.2026.04.010_bib38","doi-asserted-by":"crossref","DOI":"10.1111\/aji.70142","article-title":"Relationship between serum autotaxin levels and fasting bile acid in intrahepatic cholestasis of pregnancy","volume":"94","author":"Koksal","year":"2025","journal-title":"Am J Reprod Immunol"},{"issue":"5","key":"10.1016\/j.cld.2026.04.010_bib39","article-title":"Effectiveness of nemolizumab for refractory pruritus in a pediatric patient with atopic dermatitis after biliary atresia surgery","volume":"17","author":"Masukane","year":"2025","journal-title":"Cureus"},{"issue":"1","key":"10.1016\/j.cld.2026.04.010_bib40","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1097\/HEP.0000000000000728","article-title":"Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis","volume":"80","author":"Kremer","year":"2024","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.cld.2026.04.010_bib41","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/hep.32599","article-title":"IL-31 levels correlate with pruritus in patients with cholestatic and metabolic liver diseases and is farnesoid X receptor responsive in NASH","volume":"77","author":"Xu","year":"2023","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2026.04.010_bib42","series-title":"Itch: mechanisms and treatment","article-title":"Pruritus of cholestasis","author":"Bergasa","year":"2014"},{"issue":"2","key":"10.1016\/j.cld.2026.04.010_bib43","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/S1665-2681(19)31658-8","article-title":"Serum concentrations of substance P in cholestasis","volume":"9","author":"Trivedi","year":"2010","journal-title":"Ann Hepatol"},{"issue":"5","key":"10.1016\/j.cld.2026.04.010_bib44","doi-asserted-by":"crossref","DOI":"10.1590\/1806-9282.20242025","article-title":"Pruritus in intrahepatic cholestasis of pregnancy: the role of substance","volume":"71","author":"Eyisoy","year":"2025","journal-title":"Rev Assoc Med Bras (1992)"},{"issue":"4","key":"10.1016\/j.cld.2026.04.010_bib45","doi-asserted-by":"crossref","first-page":"327","DOI":"10.4103\/0019-5154.113971","article-title":"Intra-hepatic cholestasis of pregnancy: a comprehensive review","volume":"58","author":"Ghosh","year":"2013","journal-title":"Indian J Dermatol"},{"issue":"1","key":"10.1016\/j.cld.2026.04.010_bib46","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1186\/s13023-025-03798-x","article-title":"Psychometric validation of the worst Itch Numerical Rating Scale (WI-NRS) and other patient-reported outcome measures for assessing severity and impact of pruritus in patients with primary biliary cholangitis","volume":"20","author":"Gelhorn","year":"2025","journal-title":"Orphanet J Rare Dis"},{"issue":"7","key":"10.1016\/j.cld.2026.04.010_bib47","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1016\/j.cgh.2022.10.032","article-title":"GLIMMER: a randomized phase 2b dose-ranging trial of linerixibat in primary biliary cholangitis patients with pruritus","volume":"21","author":"Levy","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.cld.2026.04.010_bib48","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1136\/gut.2005.065862","article-title":"Development, validation, and evaluation of the PBC-40, a disease specific health related quality of life measure for primary biliary cirrhosis","volume":"54","author":"Jacoby","year":"2005","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.cld.2026.04.010_bib49","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1111\/j.1365-2133.2009.09586.x","article-title":"The 5-D itch scale: a new measure of pruritus","volume":"162","author":"Elman","year":"2010","journal-title":"Br J Dermatol"},{"issue":"11","key":"10.1016\/j.cld.2026.04.010_bib50","doi-asserted-by":"crossref","first-page":"5105","DOI":"10.1007\/s12325-022-02262-7","article-title":"Validation of the PRUCISION instruments in pediatric patients with progressive familial intrahepatic cholestasis","volume":"39","author":"Gwaltney","year":"2022","journal-title":"Adv Ther"},{"issue":"1","key":"10.1016\/j.cld.2026.04.010_bib51","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/s43856-023-00345-2","article-title":"A multimodal sensing ring for quantification of scratch intensity","volume":"3","author":"Padmanabha","year":"2023","journal-title":"Commun Med (Lond)"},{"issue":"14","key":"10.1016\/j.cld.2026.04.010_bib52","doi-asserted-by":"crossref","DOI":"10.3390\/s25144316","article-title":"Development of objective measurements of scratching as a proxy of atopic Dermatitis-A review","volume":"25","author":"Au","year":"2025","journal-title":"Sensors (Basel)"},{"issue":"9","key":"10.1016\/j.cld.2026.04.010_bib53","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1007\/s11894-019-0713-6","article-title":"Treatment of pruritus secondary to liver disease","volume":"21","author":"D\u00fcll","year":"2019","journal-title":"Curr Gastroenterol Rep"},{"issue":"10201","key":"10.1016\/j.cld.2026.04.010_bib54","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1016\/S0140-6736(19)31270-X","article-title":"Ursodeoxycholic acid versus placebo in women with intrahepatic cholestasis of pregnancy (PITCHES): a randomised controlled trial","volume":"394","author":"Chappell","year":"2019","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.cld.2026.04.010_bib55","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41575-022-00687-7","article-title":"Mechanisms of pruritus in cholestasis: understanding and treating the itch","volume":"20","author":"Beuers","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.cld.2026.04.010_bib56","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1111\/j.1478-3231.2006.01326.x","article-title":"Rifampin is safe for treatment of pruritus due to chronic cholestasis: a meta-analysis of prospective randomized-controlled trials","volume":"26","author":"Khurana","year":"2006","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.cld.2026.04.010_bib57","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0022-2275(20)30141-3","article-title":"Regulation of xenobiotic and bile acid metabolism by the nuclear pregnane X receptor","volume":"43","author":"Kliewer","year":"2002","journal-title":"J Lipid Res"},{"issue":"6","key":"10.1016\/j.cld.2026.04.010_bib58","doi-asserted-by":"crossref","first-page":"3369","DOI":"10.1073\/pnas.051551698","article-title":"The nuclear receptor PXR is a lithocholic acid sensor that protects against liver toxicity","volume":"98","author":"Staudinger","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"10.1016\/j.cld.2026.04.010_bib59","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/S0168-8278(02)00318-5","article-title":"Efficacy and safety of oral naltrexone treatment for pruritus of cholestasis, a crossover, double blind, placebo-controlled study","volume":"37","author":"Terg","year":"2002","journal-title":"J Hepatol"},{"issue":"11","key":"10.1016\/j.cld.2026.04.010_bib60","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1345\/aph.18115","article-title":"Opioid antagonists in the treatment of pruritus from cholestatic liver disease","volume":"32","author":"Terra","year":"1998","journal-title":"Ann Pharmacother"},{"issue":"6","key":"10.1016\/j.cld.2026.04.010_bib61","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1016\/j.jpainsymman.2003.05.004","article-title":"Paroxetine in the treatment of severe non-dermatological pruritus: a randomized, controlled trial","volume":"26","author":"Zylicz","year":"2003","journal-title":"J Pain Symptom Manag"},{"issue":"2","key":"10.1016\/j.cld.2026.04.010_bib62","first-page":"121","article-title":"Paroxetine for pruritus in advanced cancer","volume":"16","author":"Zylicz","year":"1998","journal-title":"J Pain Symptom Manag"},{"issue":"1","key":"10.1016\/j.cld.2026.04.010_bib63","doi-asserted-by":"crossref","first-page":"45","DOI":"10.2340\/00015555-0553","article-title":"Treatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fluvoxamine: results of an open-labelled, two-arm proof-of-concept study","volume":"89","author":"Stander","year":"2009","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"10.1016\/j.cld.2026.04.010_bib64","first-page":"22","article-title":"SSRI antidepressant medications: adverse effects and tolerability","volume":"3","author":"Ferguson","year":"2001","journal-title":"Prim Care Companion J Clin Psychiatry"},{"issue":"8","key":"10.1016\/j.cld.2026.04.010_bib65","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1016\/j.transproceed.2006.08.052","article-title":"Treatment of refractory cholestatic pruritus with molecular adsorbent recirculating system (MARS)","volume":"38","author":"Montero","year":"2006","journal-title":"Transplant Proc"},{"issue":"3","key":"10.1016\/j.cld.2026.04.010_bib66","first-page":"254","article-title":"Treatment of intractable pruritus in patients with cholestasis with molecular adsorbents recirculating system dialysis: a case series","volume":"16","author":"Antoszewska","year":"2021","journal-title":"Przegl\u0105d Gastroenterol"},{"issue":"6","key":"10.1016\/j.cld.2026.04.010_bib67","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1111\/j.1365-2036.2012.04994.x","article-title":"\u2018Out-patient\u2019 albumin dialysis for cholestatic patients with intractable pruritus","volume":"35","author":"Leckie","year":"2012","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.cld.2026.04.010_bib68","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/jca.21573","article-title":"Plasma exchange for the management of refractory pruritus of cholestasis: a report of three cases and review of literature","volume":"33","author":"Chkheidze","year":"2018","journal-title":"J Clin Apher"},{"issue":"11","key":"10.1016\/j.cld.2026.04.010_bib69","doi-asserted-by":"crossref","first-page":"3633","DOI":"10.1093\/ndt\/gfr115","article-title":"Comparison of molecular adsorbents Recirculating System (MARS) dialysis with combined plasma exchange and haemodialysis in children with acute liver failure","volume":"26","author":"Schaefer","year":"2011","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1016\/j.cld.2026.04.010_bib70","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1053\/j.gastro.2020.10.001","article-title":"Fibrates for itch (FITCH) in fibrosing cholangiopathies: a double-blind, randomized, placebo-controlled trial","volume":"160","author":"de Vries","year":"2021","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.cld.2026.04.010_bib71","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jhep.2021.01.013","article-title":"A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA","volume":"74","author":"Schattenberg","year":"2021","journal-title":"J Hepatol"},{"issue":"1","key":"10.1016\/j.cld.2026.04.010_bib72","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jhep.2025.04.025","article-title":"Safety and efficacy of elafibranor in primary sclerosing cholangitis: the ELMWOOD phase II randomized-controlled trial","volume":"84","author":"Levy","year":"2026","journal-title":"J Hepatol"},{"issue":"9","key":"10.1016\/j.cld.2026.04.010_bib73","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2306185","article-title":"Efficacy and safety of elafibranor in primary biliary cholangitis","volume":"390","author":"Kowdley","year":"2024","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.cld.2026.04.010_bib74","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1097\/HEP.0000000000000395","article-title":"Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study","volume":"78","author":"Hirschfield","year":"2023","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.cld.2026.04.010_bib75","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1056\/NEJMoa2312100","article-title":"A phase 3 trial of seladelpar in primary biliary cholangitis","volume":"390","author":"Hirschfield","year":"2024","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.cld.2026.04.010_bib76","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1002\/hep4.1305","article-title":"A randomized, controlled, phase 2 study of Maralixibat in the treatment of itching associated with primary biliary cholangitis","volume":"3","author":"Mayo","year":"2019","journal-title":"Hepatol Commun"},{"issue":"1","key":"10.1016\/j.cld.2026.04.010_bib77","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/S2468-1253(25)00192-X","article-title":"Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial","volume":"11","author":"Hirschfield","year":"2026","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2026.04.010_bib78","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.jpeds.2022.09.001","article-title":"Maralixibat treatment response in alagille syndrome is associated with improved health-related quality of life","volume":"252","author":"Kamath","year":"2023","journal-title":"J Pediatr"},{"issue":"7","key":"10.1016\/j.cld.2026.04.010_bib79","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S2468-1253(24)00080-3","article-title":"Maralixibat in progressive familial intrahepatic cholestasis (MARCH-PFIC): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Miethke","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.cld.2026.04.010_bib80","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/S2468-1253(24)00074-8","article-title":"Efficacy and safety of odevixibat in patients with Alagille syndrome (ASSERT): a phase 3, double-blind, randomised, placebo-controlled trial","volume":"9","author":"Ovchinsky","year":"2024","journal-title":"Lancet Gastroenterol Hepatol"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326126000449?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1089326126000449?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T23:34:36Z","timestamp":1784763276000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1089326126000449"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":80,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1089326126000449"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2026.04.010","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cholestatic Pruritus","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2026.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}